In this webinar, Rico Buchli, PhD, shares how next-generation soluble HLA peptide discovery platforms can strengthen early immunotherapy R&D - from target identification and confirmation to receptor/drug validation and translational decision-making.
Human leukocyte antigen (HLA)–presented peptides define one of the most powerful target spaces in immunotherapy. By enabling access to intracellular and mutation-derived antigens, HLA-peptide complexes dramatically expand what can be targeted beyond conventional surface proteins.
Dr. Buchli, Chief Scientist at HLA Protein Technologies, shares how HLA-peptide workflows help teams select targets with higher confidence, reduce off-target risk, and de-risk programs earlier, with practical examples spanning oncology, infectious disease, and autoimmunity. Participants will connect HLA-peptide target evidence to multiple T-cell–directed therapeutic modalities, such as CAR-Ts, T-cell engagers, and vaccines. You will also leave with a clearer framework for building an HLA-peptide target strategy, what “good” looks like for validation, and where these tools accelerate go/no-go decisions.
Key Topics Include:
- How HLA-peptide complexes unlock access to intracellular and neoantigen targets
- Strategies for peptide target discovery, validation, and epitope mapping to improve target prioritization
- Approaches to generating fit-for-purpose HLA–peptide reagents to accelerate immunotherapy R&D
- How soluble HLA tools de-risk T-cell–directed therapeutic modality programs
Resources
Presenters
Chief Scientific Officer
HLA Protein Technologies
Production Partner
HLA Protein Technologies Inc.
